Post-earnings recap
Reported
Thu, May 5, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss per share of $0.18, which was below expectations. The stock reacted negatively, declining by 2.92%. The lack of revenue figures and management commentary leaves uncertainty about the company's performance and future direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.18 | N/A | -28.57% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.